Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05636800

Microwave Treatment for Actinic Keratosis

This is a randomized, controlled, multi-center trial in subjects diagnosed with Actinic Keratosis (AK) where each subject serves as their own control. The trial will be conducted at 2 sites, one in Germany and one in the United States. Approximately 60 subjects will be randomized to ensure 51 subjects complete the study.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Keratosis, Actinic Keratosis Neoplasms Precancerous Conditions Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centroderm GmbH, Wuppertal, Germany

Loading trial locations.

About this study

The primary objective of this trial is to evaluate the efficacy of the Swift Microwave Treatment on resolution of Actinic Keratosis lesions.

The secondary objectives of this trial is to evaluate the efficacy, safety and tolerability of Swift Microwave treatment as a therapy for Actinic Keratosis (AK).

Eligible subjects who provide written informed consent and have 10, 12 or 14 distinct Actinic Keratosis lesions located on their scalp or hands will be randomized onto the study. Randomization of AK lesions will be stratified by side. Subjects will be randomized to treatment on half the number of AK lesions mapped located on their scalp or hands. The mapped AK lesions not randomized for treatment will receive no treatment (control).

The microwave energy applied by the Swift device will be applied to the randomized AK lesion sites for up to 2 treatments, spaced out by a 4-week interval. Follow-up is 2-months after the first treatment is administered where the AK lesions are assessed for resolution. Further follow-up visits occur at 4-months, 6-months and 12-months after the first treatment was administered where the AK lesions will be assessed for resolution or reoccurence.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of signed and dated informed consent form.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Age 18-85 years inclusive (EU); 22-85 years inclusive (US).
  • AK lesions for randomization in this study: Clinical diagnosis by a dermatologist of precancerous Actinic Keratosis.
  • Cutaneous location.
  • 10, 12 or 14 distinct AK lesions (3-6mm in diameter inclusive), for randomization in this study, located on the subjects' scalp or hands (AK lesions on the scalp and hands for randomization cannot be mixed).
  • There must be at least 2 AK lesions on the left and right side of the scalp or left and right hand.
  • An even number of distinct AK lesions (10, 12 or 14) are to be selected.
  • The maximum possible number of available distinct AK lesions should be selected (10, 12 or 14).
  • The subject may present with any number of AK lesions, however only 10, 12 or 14 distinct AK lesions will be selected for randomization. For example, if a subject presents with 21 AK lesions, an even number of distinct AK lesions are to be selected (i.e. 14 distinct AK lesions with at least 2 distinct AK lesions on the left and right side of the scalp or left and right hand).
  • If currently receiving treatment for Actinic Keratosis, agree to stop their current medication for at least 28 days prior to the start of study treatment.
  • Agrees to refrain from using any other Actinic Keratosis products or treatments during the study period, unless specified by the Investigator.
  • Agrees to refrain from using any topical metallic or ionic treatment (e.g., aluminum chloride, silver nitrate, zinc oxide) during the study period.
  • Free of any disease state or condition which, in the investigator's opinion, could impair evaluation of AK or could expose the subject to an unacceptable risk by study participation.
  • Able to perform study assessments.

Exclusion criteria

  • AK lesions at potential treatment sites on lip, nose crease, near eyes or ear.
  • Confluent AK associated with field change at potential treatment sites.
  • Fewer than 2 AK lesions on the left and right side of the scalp or left and right hand.
  • AK lesions at potential treatment sites assessed as clinically ambiguous.
  • Implantable Cardioverter Defibrillator (ICD), pacemaker or other implantable electronic devices.
  • Metal implants at site of treatment.
  • Known allergy or intolerance to microwave therapy.
  • Unstable co-morbidities (cardiovascular disease, active malignancy, vasculopathy, inflammatory arthritis).
  • Previous history of skin cancer in the study treatment or observation area.
  • Previous history of squamous cell carcinoma (SCC) or keratoacanthoma (KA) in any location.
  • Pregnancy or breast feeding.
  • Participating in another interventional study or have done so within the last 30 days.
  • Anticipated relocation or extensive travel outside of the local study area preventing compliance with study procedures.
  • Circulatory conditions affecting the acral areas - peripheral vascular disease, peripheral ischemia, vasculitis, Raynaud's, or related conditions.
  • Peripheral neuropathy.
  • Subject who is immunosuppressed (organ transplant recipients, hematologic malignancies, HIV).
  • Subject who has had any topical metallic or ionic treatment (e.g, aluminum chloride, silver nitrate, zinc oxide) within the last 6 months at potential treatment sites.
  • Subjects with AK on the scalp and who have hearing aid(s) and are unable or unwilling to remove hearing aids prior to microwave treatment.

Treatment and study plan

Swift System

Device

Localized microwave energy applied to the distinct AK lesion. Each subject will receive treatment for a maximum of 2 visits (4-week interval between treatment).

For AK lesions assessed as "Thin" AK (Olsen Grades 1 and 2): Set at 3W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions). There will be approximately 20 seconds between each repeat dose.

For AK lesions assessed as "Thick" AK (Olsen Grade 3): Set at 4W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions).

As the AK lesions may be larger than 3mm in diameter, the dose administered to one AK lesion may require overlapping applications with the applicator tip. Ensure there is approximately 20 seconds between each repeat dose administered

Primary outcomes

  1. Proportion of subjects with treatment success of Actinic Keratosis at 2 months following Swift Microwave treatment.

    Time frame: 2 months post first treatment

    Definition:

    Treatment Success: complete clearance of ≥75% Actinic Keratosis lesions treated per subject, i.e., at least 75% of the AK lesions treated are fully cleared (not partially cleared).

Secondary outcomes

  1. Proportion of subjects with treatment success of Actinic Keratosis following Swift Microwave treatment.

    Time frame: 4 and 6 months post first treatment

  2. Proportion of subjects with 100% clearance of Actinic Keratosis following Swift Microwave treatment

    Time frame: 2, 4 and 6 months post first treatment

  3. Percentage of Actinic Keratosis lesions cleared across all study lesions following Swift Microwave treatment

    Time frame: 2, 4 and 6 months post first treatment

  4. OCT Analysis as assessed by an AK Classification System

    Time frame: Baseline and 2, 4 and 6 months post first treatment

    AK Lesions classified as Not Present, AK I (Grade I mild), AK II (Grade II, moderate) or AK III (Grade III severe)

  5. Proportion of subjects with reoccurrence of any Actinic Keratosis lesions at 6 months, as classified by the blinded site investigator. The subject's AK lesion must be classified as completely resolved at 2 months to be considered a reoccurrence.

    Time frame: 6 months post first treatment

  6. Level of pain during treatment using a severity scale

    Time frame: Treatment 1 (Day 0), Treatment 2 (Day 28)

    The subject is asked to rate the worst pain experienced during treatment as None, Mild, Moderate or Severe

  7. Level of pain after treatment using a severity scale

    Time frame: Treatment 1 (Day 0), Treatment 2 (Day 28)

    The subject is asked to rate the worst pain experienced during the 10 minute period after treatment is completed as None, Mild, Moderate or Severe

  8. Duration of pain after treatment using a time period scale

    Time frame: Treatment 1 (Day 0), Treatment 2 (Day 28)

    For subjects who experienced pain after treatment, the subject is asked to rate the duration of pain experienced during the 10 minute period after treatment using the following time period scales: a few seconds, up to 1 minute, up to 2 minutes, up to 3 minutes, Still Sore.

  9. Difference in cosmetic outcomes between treated and non-treated Actinic Keratosis as classified by the independent blinded assessors using a grading system

    Time frame: 2, 4 and 6 months post first treatment

    Photographs of each treated and non-treated AK lesion will be assessed by the independent blinded assessors for cosmetic outcome as "excellent" (slight redness or pigmentation change), "good" (moderate redness or pigmentation change), "fair" (slight-to-moderate scarring, atrophy or induration), or "poor" (extensive scarring, atrophy or induration). Each assessment compares the photos taken at the current visit against the photos taken at the previous visit. The assessments by each independent blinded assessor is recorded separately.

  10. Severity and occurrence of Adverse Events

    Time frame: Up to 12 months post first treatment

  11. Evaluation of Patient Reported Outcome (PRO) at baseline and 6 months post first treatment using a rating scale

    Time frame: Baseline and 6 months post first treatment

    At Baseline, the subject will be asked to rate how their AK lesions affect their daily activities, lifestyle and mood as: none, mild, moderate and severe.

    At 6-months post first treatment, the subject will be asked to rate how their daily activities, lifestyle and mood are now affected, when compared to before study treatment as: significantly better, better, unchanged, worse, significantly worse.

    The results at baseline and at 6 months post first treatment will be evaluated.

  12. Evaluation of Quality of Life (QoL) questionnaires at baseline and 6 months post first treatment using the Dermatology Life Quality Index (DLQI) questionnaire

    Time frame: Baseline and 6 months post first treatment

    The DLQI questionnaire measures how the AK lesions have affected the subject's life over the past week. The score at baseline and at 6 months post first treatment will be evaluated.

  13. Evaluation of Cosmetic Outcome at 6 months post first treatment using a rating scale

    Time frame: 6 months post first treatment

    The subject will be asked to rate the AK lesions that were treated compared to before treatment as: significantly better, better, unchanged, worse, significantly worse.

  14. Long term follow-up of subjects with reoccurrence at 12 months as classified by the blinded site investigator

    Time frame: 12 months post first treatment

Sponsors and collaborators

Lead sponsor

Blackwell Device Consulting

Industry

Collaborators

  • Emblation Limited

Registry information

Official study title

Pivotal Study to Assess the Clinical Efficacy and Safety of Microwave Treatment for Actinic Keratosis

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Dec 5, 2022
Registry last updated
Aug 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.